3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
3
Gynecologic
3
Sarcoma
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
279
Triple Negative Breast Neoplasms
146
Neoplasm Metastasis
27
Ovarian Neoplasms
23
Carcinoma, Non-Small-Cell Lung
17
Inflammatory Breast Neoplasms
15
Pancreatic Neoplasms
12
Neoplasms
11
Endometrial Neoplasms
11
Breast Neoplasms, Male
11
Colorectal Neoplasms
8
Carcinoma, Ductal, Breast
8
Stomach Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Lung Neoplasms
7
Prostatic Neoplasms
6
Melanoma
6
Fallopian Tube Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pathologic Complete Response
5
HER2-positive Breast Cancer
5
Carcinoma, Ovarian Epithelial
5
Esophageal Neoplasms
4
Carcinoma, Lobular
4
Urinary Bladder Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Multiple Myeloma
3
Interventions
pembrolizumab
4
Nivolumab
3
Itraconazole
2
tucatinib
1
tremelimumab
1
regorafenib
1
pertuzumab
1
lenvatinib
1
larotrectinib
1
durvalumab
1
cemiplimab
1
brigimadlin
1
aflibercept
1
Trastuzumab
1
Ritonavir
1
Paclitaxel
1
Fulvestrant
1
Clinical Trials, Phase II as Topic
1
Carboplatin
1
Capecitabine
1
Antibodies
1
AZD9833
1
AZD5305
1
AZD 6244
1
ARX788
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Carboplatin
×
Breast
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled